A Phase 2 interventional study of bortezomib; pegylated liposomal doxorubicin in Multiple Myeloma, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-06.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.
Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 255th largest by enrollment of the 267 interventional ones that give a count, is one of 22 that started in 2008, is one of 137 in phase 2, and was the 92nd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Canadian Myeloma Research Group · Sites in Canada
Ages 65+
Peking University First Hospital · Sites in China
Ages 18–70
Stichting European Myeloma Network · Sites in Austria, Germany, Greece and 2 more countries
Ages 18–70
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
271 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 76 · Phase 2 176 · Phase 3 46 · Phase 4 8
First in 1999; this study’s year is marked. 22 started in 2008.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 41 across the 267 interventional studies. Of the 194 that completed or were terminated, 94 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 271 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 98th largest by enrollment of the 100 interventional ones that give a count, is one of 6 that started in 2008, is one of 32 in phase 2, and was the 21st registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
9 of the studies testing bortezomib in Multiple Myeloma that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT00734877Phase 3University of ArkansasUARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma | 2027-09 |
| NCT02718833Massachusetts General HospitalA Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 271 studies testing bortezomib in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of using pegylated liposomal doxorubicin and bortezomib in the treatment of patients with relapsed multiple myeloma who had been previously treated with bortezomib. Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of the immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone. Multiple myeloma treatment may include stem cell transplantation, however, not all patients with multiple myeloma are candidates for stem cell transplantation and many patients who receive transplants relapse. As a result, additional first and later-line therapeutic options are needed for patients who are not candidates for transplantation, or whose disease relapses after transplantation or other therapies. Pegylated liposomal doxorubicin in combination with bortezomib is approved for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. The combined use of pegylated liposomal doxorubicin and bortezomib in this study is designed to evaluate the overall response rate and safety in patients with multiple myeloma who have been previously treated with bortezomib.
The primary purpose of this study is to evaluate the overall response rate to DOXIL/VELCADE treatment in patients with relapsed multiple myeloma previously treated with VELCADE. Overall response rate is defined as the proportion of patients achieving either a complete response (CR) or partial response (PR) to treatment according to the European Group for Blood and Marrow Transplantation (EBMT) criteria. This is a single arm (all patients will receive the same drug combination and dose), multi-center (many study sites), open label (the patient and the physician know the drug treatment being received) of approximately 60 patients with multiple myeloma whose disease has progressed after initial response to VELCADE-based therapy. During each 21-day treatment cycle, patients will receive VELCADE by intravenous bolus on 4 designated days, and DOXIL by intravenous infusion on one designated day. Treatment will continue until disease progression, or the occurrence of unacceptable treatment-related toxicity or up to a total of 8 cycles of therapy. Drug doses may be delayed or dropped as needed to allow for platelet transfusions or other treatment requirements. Patients responding to treatment at study end may be evaluated for continued treatment for as long as treatment can be tolerated and they continue to respond. After discontinuation of all study drugs, patients who have not had disease progression will be followed for 6 months after receiving the last dose of study drug. The primary endpoint is overall response rate as defined by the proportion of patients achieving either a complete response or a partial response. Response will be assessed at each cycle. Safety will be monitored throughout the study by physical examination, clinical laboratory testing, and the incidence and severity of reported adverse events. Overall safety will be summarized at study-end.
During each 21-day treatment cycle, patients will receive bortezomib 1.3 mg/m2 by intravenous bolus on Days 1, 4, 8 and 11 and pegylated liposomal doxorubicin 30 mg/m2 by intravenous infusion on Day 4.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bortezomib; pegylated liposomal doxorubicin
Drug pages: Bortezomib · Liposomal doxorubicin
1.3 mg/m2 IV bolus on Days 1,4,8,11 of each 21-day cycle; 30 mg/m2 IV infusion on Day 4 of each 21 day cycle
The primary endpoint is the overall response rate defined as the partial or complete response to treatment according to EBMT criteria. Overall response will be assessed at each treatment cycle up to 8 cycles.
Time frame: Assessed at each 21-day treatment cycle up to 8 cycles and over 6 months following discontinuation of all study drugs.
Secondary endpoints include time to disease progression (treatment start to disease progression or death due to progression); best response assessed by the investigator; duration of response; and overall survival (treatment start to death by any cause).
Time frame: Day 1, Cycle 1 throughout treatment cycles and follow-up.
No study locations are listed for this record.
The record gives a start of Jul 2008, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bortezomib · Liposomal doxorubicin
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →